AstraZeneca, a global biopharmaceutical and biotechnology company, is looking to develop a computational model based on molecular glue (MG) ternary binding and kinetics, to guide decision making on project initiation, and key optimization strategies.
MG, as an innovative modality, holds significant potential in drug discovery. MGs can be characterized by distinct binding and kinetic pathways that result in ternary complex formation. Currently, the prospective and rationale discovery of MG is still in its infancy, and there is a lack of comprehensive theoretical...